← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neurop, Inc.
Atlanta, GA
$10,110,556
Total funding
9
Grants
Funding over time
peak $2.2M · FY2006–19$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,110,556 · 9
By mechanism
R44$5,020,174 · 2
U44$3,507,824 · 1
R43$917,780 · 3
R41$664,778 · 3
Investigators at Neurop, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$2,163,892
R44 · FY2017 · NS
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$1,327,699
R44 · FY2018 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$994,652
U44 · FY2013 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$931,527
U44 · FY2012 · NS
pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection$766,198
R44 · FY2006 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$748,822
U44 · FY2014 · NS
pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection$637,385
R44 · FY2007 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$393,610
U44 · FY2015 · NS
Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators$346,261
R43 · FY2013 · MH
Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators$345,731
R43 · FY2012 · MH
Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse$301,303
R41 · FY2018 · DA
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$299,541
U44 · FY2011 · NS
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics$219,338
R41 · FY2014 · AG
Evaluation of pH Dependent Neuroprotectants in SAH Model$144,137
R41 · FY2008 · NS
Neuroprotection of pH Sensitive NMDAR Antagonists in Cardiopulmonary Bypass Surge$125,788
R43 · FY2007 · NS
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$125,000
R44 · FY2019 · NS
In vivo proof of concept:pH-dependent neuroprotection$100,000
R43 · FY2004 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$86,250
U44 · FY2014 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$48,422
U44 · FY2015 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$5,000
U44 · FY2015 · NS